View all newsletters
Sign up to our newsletters

Support 110 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
18 May 2020updated 06 Oct 2020 9:45am

EU moves to approve Ebola drug for coronavirus

By Samir Jeraj

The European Union is expected to the drug remdesivir as a treatment for COVID-19. Such a move would make it the first treatment authorised for the coronavirus.

The head of the European Medicines Agency (EMA), Guido Rasi said during a hearing at the European parliament earlier today that “a conditional market authorisation” could be issued in “the coming day”. A week earlier the EMA recommended “compassionate use” of remdesivir for patients with severe COVID‑19, meaning it could be administered to patients even without authorisation.

The remdesivir drug is being developed by the US-based company Gilead Sciences. The conditional authorisation would allow the drug to be sold in the European Union for a year, without meeting the usual threshold for evidence on its side-effects or effectiveness.

Content from our partners
Unlocking the potential of a national asset, St Pancras International
Time for Labour to turn the tide on children’s health
How can we deliver better rail journeys for customers?

Select and enter your email address Your weekly guide to the best writing on ideas, politics, books and culture every Saturday. The best way to sign up for The Saturday Read is via saturdayread.substack.com The New Statesman's quick and essential guide to the news and politics of the day. The best way to sign up for Morning Call is via morningcall.substack.com Our Thursday ideas newsletter, delving into philosophy, criticism, and intellectual history. The best way to sign up for The Salvo is via thesalvo.substack.com Stay up to date with NS events, subscription offers & updates. Weekly analysis of the shift to a new economy from the New Statesman's Spotlight on Policy team. The best way to sign up for The Green Transition is via spotlightonpolicy.substack.com
  • Administration / Office
  • Arts and Culture
  • Board Member
  • Business / Corporate Services
  • Client / Customer Services
  • Communications
  • Construction, Works, Engineering
  • Education, Curriculum and Teaching
  • Environment, Conservation and NRM
  • Facility / Grounds Management and Maintenance
  • Finance Management
  • Health - Medical and Nursing Management
  • HR, Training and Organisational Development
  • Information and Communications Technology
  • Information Services, Statistics, Records, Archives
  • Infrastructure Management - Transport, Utilities
  • Legal Officers and Practitioners
  • Librarians and Library Management
  • Management
  • Marketing
  • OH&S, Risk Management
  • Operations Management
  • Planning, Policy, Strategy
  • Printing, Design, Publishing, Web
  • Projects, Programs and Advisors
  • Property, Assets and Fleet Management
  • Public Relations and Media
  • Purchasing and Procurement
  • Quality Management
  • Science and Technical Research and Development
  • Security and Law Enforcement
  • Service Delivery
  • Sport and Recreation
  • Travel, Accommodation, Tourism
  • Wellbeing, Community / Social Services
Visit our privacy Policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications.
THANK YOU